Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

What happened

Enlivex said 135 of a planned 182 patients have been randomized and given their first Allocetra injection in a Phase 2b trial for moderate-to-severe age-related knee osteoarthritis. The trial runs in the United States, Denmark and Poland, with six-month topline data expected by mid-2027.

Confirmed

Global impact / market context

Enrolling most of the planned patients moves the company closer to the readout that could validate its main product. Positive results would support regulatory talks and possibly partnerships, while delays or weak data would raise the cost and risk of funding the next stage.

Analyst inference

The trial follows positive earlier-stage data and an FDA regenerative medicine designation, which can speed reviews of promising therapies. Investors often treat late-stage enrollment updates as a sign of reduced execution risk, though the shares still depend on the eventual data.

Analyst inference

What to watch

1. Enlivex expects topline six-month data from the Phase 2b trial by mid-2027, a date that could shift if enrollment or site activity slows. Confirmed
2. Watch whether the remaining patients up to the planned 182 are randomized on schedule at sites in the United States, Denmark and Poland, since full enrollment supports the planned readout. Proposed
3. Track cash needs for the ongoing trial and later steps; a company with limited cash available may need to raise money through share sales or partnerships, which can dilute investors. Analyst inference

Evidence

• globenewswire.com